Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 65.87 Bil Enterprise Value: 59.05 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript

Sep 16, 2020 / 03:45PM GMT
Release Date Price: MXN1635.64
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Good afternoon, everyone. Thank you for joining us. I'm Tazeen Ahmad. I am one of the SMID biotech analysts here at Bank of America.

It is my pleasure to introduce our next presenting company, Ultragenyx Pharmaceuticals. Speaking for Ultragenyx today is Emil Kakkis, President and CEO. Dr. Kakkis is the founder of Ultragenyx. He founded the company in 2010 to focus on developing rare and ultra-rare disease therapeutics. The company went public in January 2014, and today does have a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high-unmet medical need and a clear biology for treatment. Emil? Hello. Thanks for joining us today.

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Thanks for having me, Tazeen. Happy to be here.

Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

So for those on the webcast who may not be as familiar with Ultragenyx, maybe we could spend a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot